Second, we demonstrated that ML120B can inhibit constitutive activation of NF-κB in indolent and aggressive lymphoma cell lines in a concentration dependent manner similar to what was observed in myeloma cells [20]. The gene discussed is NFKB1; the disease is plasma cell myeloma.